Free shipping on all orders over $ 500

HQL-79

Cat. No. M3788

All AbMole products are for research use only, cannot be used for human consumption.

HQL-79 Structure
Size Price Availability
5mg USD 190  USD190 Out of stock
10mg USD 300  USD300 Out of stock
50mg USD 930  USD930 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthase, one of two synthases involved in the production of Prostaglandin D2 (PGD2) from arachidonic acid. HQL-79 selectively inhibited the activity of recombinant H-PGDS with an IC50 of 6 μM and had almost no effect on COX-1, COX-2, m-PGES, or L-PGDS up to 300 μM. HQL-79 has anti-inflammatory activity in vitro and in vivo. HQL-79 is antiallergic and anti-inflammatory. HQL-79 displays antiasthmatic activity and potent antihistaminic properties in vivo. HQL-79 is a synthetic tetrazole compound originally prepared as a possible antihistamine. Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 inhibits the synthesis of PGD2. HQL-79 is thus a likely lead compound for the preparation of potent, selective PGE synthase inhibitors.

Chemical Information
Molecular Weight 377.48
Formula C22H27N5O
CAS Number 162641-16-9
Form Solid
Solubility (25°C) DMSO 2 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Mohri I, et al. J Neurosci. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher.

[2] Aritake K, et al. J Biol Chem. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.

[3] Matsushita N, et al. Jpn J Pharmacol. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects.

Related PGE synthase Products
Vipoglanstat

Vipoglanstat (BI 1029539) is an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1; IC50 = ≤0.5 nM in isolated human whole blood). Vipoglanstat reduces LPS-induced increases in the influx of neutrophils and levels of cytokines in bronchoalveolar lavage fluid (BALF), as well as the expression of PTGES, the gene encoding mPGES-1, Cox2, and Icam1 in the lung parenchyma, in a human PTGES knock-in mouse model of acute lung injury when administered at a dose of 30 mg/kg.

mPGES1-IN-7 

mPGES-1-IN-2 is a benzimidazole-based mPGES-1 inhibitor that also inhibits adipophysin PGD synthase (I-PGDS) (5 μM, IR=60 %).

(E)-KME-4

(E)-KME-4 is a potent inhibitor of prostaglandin synthetase (PGS) with an IC50 of 0.28 μM; also inhibits 5-lipoxygenase with an IC50 of 1.05 μM.

Friluglanstat

Friluglanstat is a prostaglandin E synthase (mPGES-1) inhibitor, with anti-inflammatory activity.

UT-11

UT-11 is a potent and brain-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: HQL-79 supplier, PGE synthase, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.